In recent years polyurethane microstructures (PM) have gained increasing attention in the pharmaceutical field due to the importance of their practical application. Since finding that such a formulation with genistein could improve its applications, we have conducted a preliminary study regarding the in vitro antiproliferative (MCF7, MDA-MB-231 and T47D) and antimicrobial (Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Salmonella enteritidis (D), Bacillus subtilis, B. cereus, and Candida albicans) activity in order to test whether polyurethane micro structuresre present a good option for further modulation of genistein's bioavailability. It was concluded that the polyurethane micro structures are a bad in vitro partner for the isoflavone genistein.
Medicinal plants provide a wide range of active agents for a variety of pathologies [1, 2] . As reported by the World Health Organization (WHO), 60% to 80% of the population call for natural medicine in the case of its primary healthcare needs [3] .The isoflavone genistein (4',5,7-trihydroxyisoflavone) is the aglycone of the heteroside genistin. It can be found mainly in plants of the Fabaceae family being best represented in soybean (Glycine max L. Merr.) seeds [4] . This compound, with a phytoestrogen type structure, has been intensively studied over the past years. Researchers have reported: anti-osteoporotic, cardio-protective, photo-protective, antiinflammatory, antioxidant, and anti-cancer properties. The compound is extensively used in supplements for counteracting the undesirable effects that occur at menopause [5, 6] . Furthermore, genistein is in clinical studies for a wide range of cancer types (www.clinicaltrials.gov). In terms of physico-chemical properties, genistein is a lipophilic compound, a feature which has raised bioavailability issues over time [7] .
In recent years polyurethane microstructures (PM) have gained increased attention in the pharmaceutical field due to the importance of their practical applications [8] . However, what recommends this kind of structure? Depending on the type of polyurethane microstructure they can offer: (1) protection of the biologically active compound to external agents (for example, UV radiation, strong acidic or alkaline environments; (2) the possibility of amending the lipo-or water-solubility of encapsulated compounds;(3) drug delivery targeted to a specific receptor; (4) delayed activity of the encapsulated drug given the use of transport vehicles having a low speed of degradation [9, 10] .
Since finding that such a formulation for genistein could improve its applications, we have conducted a preliminary study to assess whether polyurethane microstructures represent a good or a bad in vitro partner for genistein. Polyurethane microstructures with a yield of encapsulation of 68.3% genistein (w/w) were prepared. It was found that the two samples contained only one population each: 202±23 nm for the PM sample and 231±17 nm for the Gen-PM sample.
DSC, SEM, and X-ray analysis are frequently employed in the evaluation of the crystalline state of a solid substance [11, 12] .The inclusion of genistein inside polymeric microparticles has been analyzed by the above mentioned techniques. The same techniques are frequently used in the evaluation of polymeric carriers, as well as inclusion complexes, offering precious information in terms of the inclusion degree of the active substance [13, 14] . The SEM analysis revealed that genistein consists of crystalline particles of irregular shape and size while the polyurethane compound consists of amorphous, conglomerated, spherical particles, forming a matrix, with homogenous surface. Genistein's encapsulation resulted in voluminous spherical microparticles, with smooth surfaces; one can notice the absence of crystalline particles, all the genistein being included into the polyurethane microparticles, leading to highquality composites (Figure 1 ).
Based on DSC analysis, genistein (G1) reveals a sharp endothermic peak, corresponding to its decomposition, which starts at around 303°C. The empty polyurethane microparticles (G2) show a melting point at around 275°C, as revealed by a small and flattened endothermic peak. After the inclusion of genistein inside the polyurethane microparticles, the sharp endothermic point assimilated to genistein disappears completely, indicating the complete inclusion of the active compound inside the carrier's particles. Also, one can notice the almost complete disappearance of the polyurethane peak, with a decrease of the transition enthalpy of around 40 J/g. Moreover, the onset temperature of the polyurethane melting process switches from 275°C to 269°C, indicating a slight influence of the loading compound,genistein, on the particles' thermal stability ( Figure 2 ). The X-ray diffractogram of genistein (G1) shows a typical pattern of a crystalline substance with sharp, distinct peaks ( Figure 3 ). The polyurethane matrix reveals an amorphous character, as shown by an almost flat diffractogram. The inclusion of genistein into the polyurethane microparticles leads to the disappearance of all genistein's peaks, indicating the absence of free genistein particles and pointing to the conclusion that the entire active drug has been incorporated inside the polymer carrier.
All procedures (SEM, DSC, X-ray) have shown that genistein was trapped inside the polyurethane particles, which may act as carrier for the active compound. starting from the concentration of 10 µM. The percentage of inhibition is almost doubling at the concentration of 30 µM, namely 41.8±1.0%. The third analyzed cell line was the human breast carcinoma, MDA-MB-231; at the lowest employed concentration, 10 µM, genistein was most active on this cell line, with a 25.2±2.3 %percentage of inhibition. Also, the inhibition was considerable at 30 µM, namely 43.6±2.6%. As shown in Figure 4 , the polyurethane microstructures (PM) (white columns) did not have any significant effect on the proliferation of the tested cell lines. Incorporation of genistein in these polyurethane microstructures (PM) proved to be a bad choice in terms of antiproliferative activity, since the inhibition percentage for Gen-PM significantly decreased for all three cell lines, at both concentrations, with no exception, as compared with pure genistein. Results are as follows: (i) for MCF7 cell line: -8.2±3.4% for 10 µM genistein, -10.6±5.9% for 30 µM genistein; (ii) for T47D cell line: -4.2±1.9% for 10 µM genistein, -0.2±1.5% for 30 µM genistein; (iii) for MDA-MB-231 cell line: 2.3±6.0% for 10 µM genistein, 11.6±5.5% for 30 µM genistein.
The present study proves that genistein is an in vitro active compound, using different breast cancer cell lines. This aspect is well documented by previous studies. Peterson et al. proved that the inhibition of human breast cancer cells is independent of estrogen receptors and the multi-drug resistance gene [15] . Zavaet al. showed that genistein, over a physiologically relevant concentration range, has estrogen agonist and cell growth-inhibitory activity on different human breast cancer cells [16] . The inhibition of breast cancer cells, both in vitro and in vivo, was reported by several research groups [17, 18] . On the other hand, some groups reported that genistein stimulates breast cancer cell growth [19, 20] . The novelty of the current study resides in the description of genistein's in vitro activity against different breast cancer cells after incorporation into polyurethane microstructures. The potential benefits of this incorporation have been explained in the introduction section, based on previous studies reported in the scientific literature. Paiphansiri et al. have shown the increased uptake of fluorescent polyurethane microstructures in the case of HeLa cells, leading to the idea that polyurethane microstructures could be successfully exploited as biocarriers [21] . Rosenbauer et al. depicted the controlled release from this type of structures via pH-, UV-light-or temperature-induced stimuli [22] . Padoiset al. described the in vitro controlled release and antibacterial activity of chlorhexidine salt-loaded polyurethane microstructures [23] . In the present study, after a 72h incubation period, encapsulation proved to be a bad choice, since the inhibition index of the formulation decreased considerably when compared with pure genistein. Also, longer incubation periods were tested in order to see a possible controlled release, also with poor results (data not shown).
Also, in terms of antimicrobial activity, pure and encapsulated genistein were tested for their antibacterial activity. We can conclude that polyurethane microstructures (PM) are a bad partner for the isoflavonoid genistein. By using the dilution method, among the six mentioned tested strains, pure genistein was active on Bacillus subtilis, B. cereus,and Candida albicans at the highest tested concentration, namely 10mM. When further dilutions were performed, the antimicrobial activity was completely lost. At the same concentration, in all cases, a total loss of activity was noticed after the encapsulation of genistein into the microstructures. Hong et al. reported antibacterial activity on Staphylococcus aureus and Bacillus anthracis, while the growth of Lactobacillus reuteri, Escherichia coli, Shigella sonnei, and Klebsiella pneumoniae was not altered in the presence of genistein [24] . Additionally, genistein was reported as an anti-staphylococcal agent [25] . This study proves that the antimicrobial activity of genistein is also affected by its inclusion inside the polyurethanemicrostructures, leadingto a decreased biologicalactivity.
Alltogether, thepresented data show thattheuse of these microstructures as carriers affects, in a negative manner, the biological activity of genistein at the same dose as that used for the pure compound. An explanation of this behavior could be the lack of genistein release from these structures; therefore, the active compound is unable to exercise its biological activity, being kept inside the microparticles. We thus conclude that the polyurethane microstructures are a bad in vitro carrier partner for genistein.
Experimental

Preparation of thegenistein-polyurethanemicrostructures:
Ethylene glycol (EG) was obtained from Lach-Ner (Czech R.), 1,4butanediol (1,4-BD) from Carl Roth (Germany), polyethylene glycol (PEG 200), isophorone diisocyanate (IPDI), and Tween ® 20 from Merck (Germany), and genistein from Extrasynthese (France). The compounds were not purified. The synthesis of microstructures was a multi-step process [8, 9] : an aqueous (0.4 mL EG, 0.4 mL 1,4-BD, 1.2 mL PEG 200, 1.5 mL Tween ® 20 in 40 mL water) and an organic phase (1.8 mL IPDI in 20 mL acetone) were magnetically stirred (400 rpm) and preheated at 40 o C, separately. The organic phase was rapidly injected into the aqueous phase (the moment when microstructures are formed). Stirring was continued for a further 4 h to assure the completion of chemical reactions. Finally, products were washed with distilled water, three times, and dried in a lab oven at 110 o C for 6 h. The method was used twice: for a sample of empty polyurethane microstructures (PM) and for a sample of microstructures with genistein (Gen-PM). The Gen-PM sample contained 0.185 g genistein, which was added to the organic phase.
Microparticle size measurements: A Vasco particle size analyzer (Cordouan Tech., France) was used to find the size of the microparticles, with and without genistein. Samples were used in solutions 1:100, w/w, in ethanol and with the following settings: temperature (25 o C), laser power (80%), time interval (18µs), 290 channels, analysis mode (Pade-Laplace), and acquisition mode (continuous). Samples were not centrifuged. Measurements were made in triplicate.
Yield of encapsulation:
The total amount of genistein (T) was determined after the microparticles dissolution in isopropanol, followed by 30 min of ultrasound; free-genistein (F) was determined after separation of loaded-microparticles from the aqueous medium by ultracentrifugation at 45000 rpm for 20 min at 20•C; finally, the samples were evaluated using a 9100 Young Lin HPLC with an Agilent Zorbax C18 Column 150x4.6 mm). Methanol was the mobile phase with a flow rate of 1 mL/min. The UV detector was set at 280 nm. The formula of Bouchemal et al. [8] was used to evaluate the yield of encapsulation (Y): Y = [(T-F)/T]·100.
Scanning electron microscopy (SEM) assay:
A JEM 100B electron microscope (JEOL Ltd., Japan) was used, functioning on scanning technique (JEM-ASID) with an accelerating voltage of 6 kV. Images were magnified by 200-10.000 times.
Differential scanning calorimetry:
A Mettler Toledo STAR Thermal Analysis System, DSC 821(Switzerland) was used. The carrier gas was argon, the heating rate 5ºC / min, and the sample weight 2-5 mg. Examinations were made between 25-300ºC.
X-ray diffraction:
A Philips PW 1710 diffractometer was used to obtain X-ray-diffraction patterns. The tube anode was Cu with Kα = 1.54242 Å. The curves were acquired employing a tube voltage of 50 kV and 40 mA of tube current in step scan mode (step size 0.035, counting time 1 s per step).
Cell culture and MTT antiproliferative assay:
Antiproliferative assays were performed as described before [15] . Briefly, human breast cancer cell lines (MCF7, MDA-MB-231 and T47D, all purchased from the European Collection of Cell Cultures, Salisbury, UK) were maintained in minimal essential medium supplemented with 10% fetal bovine serum (FBS), 1% non-essential amino-acids and an antibiotic-antimycotic mixture. All the chemicals, if otherwise not specified, were purchased from Sigma-Aldrich Ltd. (Budapest, Hungary). The cells were grown in a humidified atmosphere of 5% CO 2 at 37ºC. Cells were seeded onto 96-well plates at a density of 5000 cells/well and allowed to stand overnight, after which the medium containing the test compound was added. After a 72h incubation, viability was determined by the addition of 20µL of [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] solution (5 mg/mL) [26] . The precipitated formazan crystals were solubilised in DMSO and the absorbance was determined at 545 nm with an ELISA reader. All calculations and statistical analyses were performed by means of Graph Pad Prism 4.0 (Graph Pad Software; San Diego, CA, USA).Results are presented as mean ± standard deviation.Student's t test was used to determine the statistical difference between the various experimental groups;*, ** and *** indicate p<0.05, p<0.01 and p<0.001.
In vitro antibacterial activity: The samples (Gen, PM, Gen-PM) were screened for their antimicrobial activity against 6 bacterial strains, Staphylococcus aureus (ATCC 25923), Escherichia coli (ATCC25922), Pseudomonas aeruginosa (ATCC 27853), Salmonella enteritidis (D) ATCC 13076, Bacillus subtilis 6633, B. cereus 14579, and Candida albicans ATCC 10231 employing the dilution method. The bacterial strains employed in this experiment were prepared from 24h old cultures. Suspensions were adjusted to a McFarland's standard of 0.5 (a final bacterial concentration of 1-2 x 108 CFU/mL). The final dilution of 1:200 bacteria in Muller-Hinton broth (Sanimed, Romania, Bucharest) was incubated at 37°C. This ensured approximately 5×10 5 CFU/mL. Two hundred μL bacterial suspension was distributed to 200μL of test medium containing serial two-fold dilutions of test compounds inside glass test tubes. These tubes were incubated for 18h at 37°C. The evaluated concentrations were 0.63mM, 1.25 mM; 2.5mM; 5mM and 10mM. For negative control 20 µL of DMSO was introduced into a tube with 200µL of bacterial suspension and 180µL of nutrient medium. Duplicate tests were performed for all bacterial strains.
